Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...

Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye ...

Aflibercept is a soluble decoy fusion protein that binds all isoforms of vascular endothelial growth factor (VEGF) with a greater binding affinity than ranibizumab. Intravitreal aflibercept is US Food ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they know why. Photo by Adobe Stock/HealthDay News Current treatments ...

A Massachusetts General Hospital (MGH) investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by an overgrowth of blood vessels in the ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...